Show simple item record

dc.contributor.authorGrewal, Ramandip
dc.contributor.authorBuchan, Sarah A
dc.contributor.authorNguyen, Lena
dc.contributor.authorNasreen, Sharifa
dc.contributor.authorAustin, Peter C
dc.contributor.authorBrown, Kevin A
dc.contributor.authorGubbay, Jonathan
dc.contributor.authorLee, Nelson
dc.contributor.authorSchwartz, Kevin L
dc.contributor.authorTadrous, Mina
dc.contributor.authorWilson, Kumanan
dc.contributor.authorWilson, Sarah E
dc.contributor.authorKwong, Jeffrey C
dc.date.accessioned2024-06-24T16:35:14Z
dc.date.available2024-06-24T16:35:14Z
dc.date.issued2023-10-05
dc.identifier.citationGrewal R, Buchan SA, Nguyen L, Nasreen S, Austin PC, Brown KA, Gubbay J, Lee N, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC. Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study. J Infect Dis. 2024 Feb 14;229(2):394-397. doi: 10.1093/infdis/jiad419. PMID: 37798119; PMCID: PMC10873169.en_US
dc.identifier.issn0022-1899
dc.identifier.eissn1537-6613
dc.identifier.doi10.1093/infdis/jiad419
dc.identifier.pmid37798119
dc.identifier.urihttp://hdl.handle.net/20.500.12648/14975
dc.description.abstractWe estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged ≥50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines.en_US
dc.language.isoenen_US
dc.publisherOxford University Press (OUP)en_US
dc.relation.urlhttps://academic.oup.com/jid/article/229/2/394/7292964en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCOVID-19en_US
dc.subjectomicronen_US
dc.subjectbivalenten_US
dc.subjectmRNAen_US
dc.subjectvaccine effectivenessen_US
dc.titleEffectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Studyen_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleThe Journal of Infectious Diseasesen_US
dc.source.volume229
dc.source.issue2
dc.source.beginpage394
dc.source.endpage397
dc.description.versionVoRen_US
refterms.dateFOA2024-06-24T16:35:16Z
dc.description.institutionSUNY Downstateen_US
dc.description.departmentEpidemiology and Biostatisticsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.issue2en_US


Files in this item

Thumbnail
Name:
jiad419.pdf
Size:
383.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/